Illumina, Inc. (NASDAQ:ILMN - Get Free Report) shares hit a new 52-week low during mid-day trading on Wednesday after Barclays lowered their price target on the stock from $100.00 to $77.00. Barclays currently has an underweight rating on the stock. Illumina traded as low as $69.38 and last traded at $70.30, with a volume of 3213335 shares changing hands. The stock had previously closed at $73.45.
Several other research firms have also weighed in on ILMN. Robert W. Baird reduced their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 5th. Royal Bank of Canada lowered their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, April 8th. Piper Sandler upped their target price on Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Finally, Guggenheim decreased their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $138.70.
Read Our Latest Stock Analysis on Illumina
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bleakley Financial Group LLC acquired a new position in shares of Illumina during the fourth quarter worth approximately $751,000. Van ECK Associates Corp raised its stake in Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock valued at $20,347,000 after acquiring an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC acquired a new position in Illumina during the 4th quarter worth $1,464,000. Allworth Financial LP increased its holdings in shares of Illumina by 720.7% during the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after purchasing an additional 6,263 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Illumina during the fourth quarter valued at about $448,000. 89.42% of the stock is owned by institutional investors and hedge funds.
Illumina Stock Up 4.9 %
The firm's fifty day moving average is $88.58 and its two-hundred day moving average is $122.25. The firm has a market cap of $11.85 billion, a price-to-earnings ratio of -9.74, a P/E/G ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
About Illumina
(
Get Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
